TNXP
Tonix Pharmaceuticals Holding Corp.
stockNASDAQ
tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 7.70 | 2026-10-06 | -20.40% | 3.750 |
| 1M | 11.73 | 2026-09-14 | -47.78% | -0.650 |
| 3M | 11.71 | 2026-07-13 | -47.67% | 1.217 |
| 6M | 12.98 | 2026-04-13 | -52.81% | 1.315 |
| 1Y | 20.06 | 2025-10-13 | -69.47% | 1.939 |
| 2Y | 15.00 | 2024-10-14 | -59.17% | — |
| 5Y | 359,936.00 | 2021-10-13 | -100.00% | 1.264 |
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) stock price today is $6.13, and today's volume is 1,074,110. TNXP is down 7.756% today. The 30 day average volume is 610,539. TNXP market cap is $105.05M with 17.15M shares outstanding.